Here is the principal investigator of the study. S
Post# of 72440
Professor Howard Stevens is Chairman of BDD Pharma and Emeritus Professor of Drug Delivery at the University of Strathclyde. Prior to joining the University in 1995, he worked 25 years in the Pharmaceutical Industry, holding a number of high level development positions in the UK and Europe [Boots Company, ER Squibb, Synthélabo (Paris), Scherer DDS].
His research interests are in the development of oral controlled release preparations and in understanding in-vivo performance in man using gamma scintigraphy and pharmacokinetics. He has published widely and is named inventor on over 20 drug delivery patents.
He is a Fellow of the Royal Pharmaceutical Society of Great Britain and the Royal Society of Chemistry. He has served on MHRA regulatory committees and as Chairman of the Academy of Pharmaceutical Sciences in 2001. He received the Nexxus Life-Time Achievement Award (2011) in recognition of his contribution to the Life Sciences business sector in Scotland.